Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 7, 2013, Pages 784-793

  Gordon, S C ^a   Hamzeh, F M ^b   Pockros, P J ^c   Hoop, R S ^b   Buikema, A R ^d   Korner, E J ^b   Terrault, N A ^e  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b GENENTECH INC   (United States)

^c SCRIPPS CLINIC   (United States)

^d OPTUM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON; RIBAVIRIN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COMORBIDITY; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG POTENCY; END STAGE LIVER DISEASE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DATABASES, FACTUAL; DNA-BINDING PROTEINS; DROSOPHILA PROTEINS; END STAGE LIVER DISEASE; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84883488333     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12454     Document Type: Article

References (31)

1. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS,. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-82.
2. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F,. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008; 47: 1128-35.
3. Kanwal F, Hoang T, Kramer JR, et al,. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140: 1182-8.
4. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD,. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-8.
5. Verna EC, Brown RS Jr,. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006; 10: 919-40.
6. El-Serag HB,. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007; 37 (Suppl. 2): S88-94.
7. Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM,. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008; 8: 958-76.
8. Eheman C, Henley SJ, Ballard-Barbash R, et al,. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012; 118: 2338-66.
9. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW,. Hepatitis C virus testing of persons born during 1945 to 1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012; 157: 817-22.
10. Lee MH, Yang HI, Lu SN, et al,. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206: 469-77.
11. Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E,. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther 2013; 37: 647-52.
12. Guiltinan AM, Kaidarova Z, Custer B, et al,. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008; 167: 743-50.
13. Mehta SH, Genberg BL, Astemborski J, et al,. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-33.
14. Grebely J, Raffa JD, Lai C, et al,. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352-8.
15. Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB,. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol 2012; 56: 320-5.
16. Arora S, Thornton K, Murata G, et al,. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364: 2199-207.
17. McGowan CE, Monis A, Bacon BR, et al,. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology 2013; 57: 1325-32.
18. Aronsohn A, Jensen D,. Informed deferral: a moral requirement for entry into the hepatitis C virus treatment warehouse. Hepatology 2012; 56: 1591-2.
19. Morgan TR, Ghany MG, Kim HY, et al,. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.
20. Kimer N, Dahl EK, Gluud LL, Krag A,. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open 2012; 2: e001313.
21. van der Meer AJ, Veldt BJ, Feld JJ, et al,. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.
22. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V,. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011; 45: e17-24.
23. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI,. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011; 17: 531-46.
24. McCombs JS, Yuan Y, Shin J, Saab S,. Economic burden associated with patients diagnosed with hepatitis C. Clin Ther 2011; 33: 1268-80.
25. Gordon SC, Pockros PJ, Terrault NA, et al,. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012; 56: 1651-60.
26. Quan H, Sundararajan V, Halfon P, et al,. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-9.
27. Blough DK, Madden CW, Hornbrook MC,. Modeling risk using generalized linear models. J Health Econ 1999; 18: 153-71.
28. Graubard BI, Korn EL,. Predictive margins with survey data. Biometrics 1999; 55: 652-9.
29. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD,. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012; 156: 279-90.
30. Talal AH, LaFleur J, Hoop R, et al,. Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV infected, evaluated patients. Aliment Pharmacol Ther 2013; 37: 473-81.
31. Louie KS, St. Laurent S, Forssen UM, Mundy LM, Pimenta JM,. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis 2012; 12: 86.